AnaptysBio (ANAB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Jun, 2026Executive summary
Annual meeting scheduled for August 11, 2026, with proxy materials available online and by request.
Shareholders of record as of June 22, 2026, are eligible to vote on key proposals.
Voting matters and shareholder proposals
Election of two Class III directors for three-year terms: Hollings Renton and John P. Schmid.
Ratification of KPMG LLP as independent auditor for fiscal year ending June 30, 2027.
Advisory vote on executive compensation (say-on-pay).
Approval of an amendment to the 2017 Equity Incentive Plan.
Board of directors and corporate governance
Board recommends voting in favor of all four proposals presented at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from AnaptysBio
- Rosnilimab showed record efficacy and strong safety in phase II-B/2b RA trial; more data Q2 2025.ANAB
Study Update8 Jul 2026 - Shareholders will vote on directors, auditor ratification, executive pay, and equity plan changes.ANAB
Proxy filing29 Jun 2026 - Spin-off completed; Jemperli royalties up 44%, net loss $52.9M, $100M buyback plan.ANAB
Q1 202612 May 2026 - Company to split, with strong Jemperli royalties and ANB033 clinical data expected in Q4.ANAB
Leerink Global Healthcare Conference 202611 Mar 2026 - Separation into biopharma and royalty entities unlocks value, with strong clinical and royalty catalysts.ANAB
Corporate presentation10 Mar 2026 - Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth.ANAB
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - Business split, strong JEMPERLI royalties, and key clinical milestones set for 2024.ANAB
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - Q2 2026 spin-off, strong Jemperli royalties, and improved Q4 net income highlight results.ANAB
Q4 20253 Mar 2026 - Separation in Q2 will unlock value from Jemperli royalties and advance a promising clinical pipeline.ANAB
Piper Sandler Virtual Novel Targets in Immunology Symposium12 Feb 2026